John Zajecka | Psychiatrist.com

Article

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

Original Research

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

Article

Clinical Management of Antidepressant Discontinuation

Original Research

Discontinuation Symptoms After Treatment With Serotonin Reuptake Inhibitors: A Literature Review

Original Research

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

Article

Importance of Establishing the Diagnosis of Persistent Anxiety

Article

Possible Biological Mechanisms of the Serotonin Reuptake Inhibitor Discontinuation Syndrome

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Article

Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Hypothetical Definition

Original Research

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

Article

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Original Research

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in some patients.